Posted July 23, 2021
Pfizer’s proposal for a booster dose came on the heels of a finding by Israel’s Ministry of Health that BNT162b2 has proven to be only 64 percent effective in preventing symptomatic infections of COVID-19. The 64 percent rate is much lower than the 95 percent efficacy rate reported by Pfizer during the clinical trials for its product last year. This would, at least in part, explain why nearly half of the people in Israel being infected with coronavirus are those who have been fully vaccinated. The Pfizer/BioNTech shot is simply not providing the kind of high level of protection that was initially advertised. Read more.